Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Momin

Showing results (11-20 of 16) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 16 results.
Infection and Immunity|March 18, 2009
Genetically modified L3,7 and L2 lipooligosaccharides from Neisseria meningitidis serogroup B confer a broad cross-bactericidal responseV Weynants, P Denoël, N Devos, et al.
The Journal of General Virology|March 31, 1998
Evaluation of a candidate human immunodeficiency virus type 1 (HIV-1) vaccine in macaques: effect of vaccination with HIV-1 gp120 on subsequent challenge with heterologous simian immunodeficiency virus-HIV-1 chimeric virusE J Stott, N Almond, K Kent, et al.
Journal of Virology|March 1, 1996
Protection against lethal simian immunodeficiency virus SIVsmmPBj14 disease by a recombinant Semliki Forest virus gp160 vaccine and by a gp120 subunit vaccineS P Mossman, F Bex, P Berglund, et al.
The American Journal of Tropical Medicine and Hygiene|February 16, 2000
A phase I safety and immunogenicity trial with the candidate malaria vaccine RTS,S/SBAS2 in semi-immune adults in The GambiaJ F Doherty, M Pinder, N Tornieporth, et al.
AIDS (London, England)|April 16, 1998
A clinically relevant HIV-1 subunit vaccine protects rhesus macaques from in vivo passaged simian-human immunodeficiency virus infectionP Mooij, M van der Kolk, W M Bogers, et al.
The Journal of Infectious Diseases|November 7, 1998
Long-term efficacy and immune responses following immunization with the RTS,S malaria vaccineJ A Stoute, K E Kester, U Krzych, et al.
Pageof 2

Showing results (11-20 of 16) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 16 results.
Infection and Immunity|March 18, 2009
Genetically modified L3,7 and L2 lipooligosaccharides from Neisseria meningitidis serogroup B confer a broad cross-bactericidal responseV Weynants, P Denoël, N Devos, et al.
The Journal of General Virology|March 31, 1998
Evaluation of a candidate human immunodeficiency virus type 1 (HIV-1) vaccine in macaques: effect of vaccination with HIV-1 gp120 on subsequent challenge with heterologous simian immunodeficiency virus-HIV-1 chimeric virusE J Stott, N Almond, K Kent, et al.
Journal of Virology|March 1, 1996
Protection against lethal simian immunodeficiency virus SIVsmmPBj14 disease by a recombinant Semliki Forest virus gp160 vaccine and by a gp120 subunit vaccineS P Mossman, F Bex, P Berglund, et al.
The American Journal of Tropical Medicine and Hygiene|February 16, 2000
A phase I safety and immunogenicity trial with the candidate malaria vaccine RTS,S/SBAS2 in semi-immune adults in The GambiaJ F Doherty, M Pinder, N Tornieporth, et al.
AIDS (London, England)|April 16, 1998
A clinically relevant HIV-1 subunit vaccine protects rhesus macaques from in vivo passaged simian-human immunodeficiency virus infectionP Mooij, M van der Kolk, W M Bogers, et al.
The Journal of Infectious Diseases|November 7, 1998
Long-term efficacy and immune responses following immunization with the RTS,S malaria vaccineJ A Stoute, K E Kester, U Krzych, et al.
Pageof 2